Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5 Years Adjuvant Imatinib in High-Risk GIST
NCT05385549Phase 2Recruiting
- Sponsor
- Asan Medical Center
- Start
- Sep 2022
- Primary completion
- Apr 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in gastrointestinal stromal tumor (GIST), sponsored by Asan Medical Center. Primary endpoint: Progression-Free Survival at 5 years. Started Sep 2022; status: recruiting.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT05385549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05385549.